Literature DB >> 10424307

An epidemic of acute haemorrhagic conjunctivitis caused by enterovirus 70 in Okinawa, Japan, in 1994.

E Uchio1, K Yamazaki, H Ishikawa, I Matsunaga, Y Asato, K Aoki, S Ohno.   

Abstract

BACKGROUND: Although enterovirus 70 (EV70) has been identified as the major aetiological agent of acute haemorrhagic conjunctivities (ACH),no EV70 strain has been isolated by cell culture method since 1988. Therefore, recent clinical and epidemiological characteristics of AHC caused by EV70 have not been clarified.
METHODS: Clinical and serological studies were carried out on patients during the AHC epidemic in Okinawa, Japan, in 1994 in which 7509 cases were reported by national epidemiological surveillance. EV70 was confirmed as the causative agent by reverse-transcription polymerase chain reaction.
RESULTS: The 11-15 years age group contained the highest number of cases (62% of the total). Conjunctival hyperaemia was present in all patients, and subconjunctival haemorrhage, superficial punctate keratitis and preauricular lymphadenopathy were present in 24.0%, 11.7% and 9.3% of AHC cases, respectively. No neurological complication was observed in this epidemic. Out of 31 paired serum samples, 10 pairs showed a fourfold rise in antibody level to EV70. None of the paired serum samples showed a fourfold rise in antibody level to Coxsackie A24 variant virus.
CONCLUSION: These findings demonstrate that the clinical features of AHC observed in this study were milder than those reported previously, in contrast to the high transmission rate during an epidemic. Changes in clinical features of AHC, such as a low incidence of subconjunctival haemorrhage and disappearance of neurological complications, might be due to biological transformation of EV70. It should be noted that EV70 is still an important aetiological agent of explosive epidemics of AHC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10424307     DOI: 10.1007/s004170050280

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  8 in total

1.  Sialic acid functions in enterovirus 70 binding and infection.

Authors:  David A Alexander; Kenneth Dimock
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

Review 2.  Treatment of viral conjunctivitis with antiviral drugs.

Authors:  Chrysanthi L Skevaki; Ioanna E Galani; Michail V Pararas; Konstantina P Giannopoulou; Athanassios Tsakris
Journal:  Drugs       Date:  2011-02-12       Impact factor: 9.546

3.  The change of etiological agents and clinical signs of epidemic viral conjunctivitis over an 18-year period in southern Taiwan.

Authors:  Cheng-Hsien Chang; Kuei-Hsiang Lin; Min-Muh Sheu; Wen-Loong Huang; Huei-Zu Wang; Chen-Wu Chen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-05-27       Impact factor: 3.117

Review 4.  The epidemiology of non-polio enteroviruses: recent advances and outstanding questions.

Authors:  Margarita Pons-Salort; Edward P K Parker; Nicholas C Grassly
Journal:  Curr Opin Infect Dis       Date:  2015-10       Impact factor: 4.915

5.  Virological and epidemiological analysis of coxsackievirus A24 variant epidemic of acute hemorrhagic conjunctivitis in Okinawa, Japan, in 2011.

Authors:  Kazuhiro Harada; Tsuguto Fujimoto; Yoshimori Asato; Eiichi Uchio
Journal:  Clin Ophthalmol       Date:  2015-06-15

6.  Acute hemorrhagic conjunctivitis: anti-coxsackievirus A24 variant secretory immunoglobulin A in acute and convalescent tear.

Authors:  Marlyn P Langford; Edwin A Anders; Maxwell A Burch
Journal:  Clin Ophthalmol       Date:  2015-09-10

Review 7.  Selective human enterovirus and rhinovirus inhibitors: An overview of capsid-binding and protease-inhibiting molecules.

Authors:  Shin-Ru Shih; Shu-Jen Chen; Gholam Hossein Hakimelahi; Hsing-Jang Liu; Chen-Tso Tseng; Kak-Shan Shia
Journal:  Med Res Rev       Date:  2004-07       Impact factor: 12.944

8.  Structure of Human Enterovirus 70 and Its Inhibition by Capsid-Binding Compounds.

Authors:  Tibor Füzik; Jana Moravcová; Sergei Kalynych; Pavel Plevka
Journal:  J Virol       Date:  2022-08-08       Impact factor: 6.549

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.